airflusal forspiro 50+500 mikrogram inhalationspulver, afdelt
2care4 aps - fluticasonpropionat, salmeterol - inhalationspulver, afdelt - 50+500 mikrogram
airflusal forspiro 50+500 mikrogram inhalationspulver, afdelt
sandoz a/s - fluticasonpropionat, salmeterol - inhalationspulver, afdelt - 50+500 mikrogram
aphiahsone 50 mikrogram/dosis næsespray, suspension
glenmark arzneimittel gmbh - mometasonfuroat monohydrat - næsespray, suspension - 50 mikrogram/dosis
benarhin 32 mikrogram/dosis næsespray, suspension
mcneil denmark aps - budesonid - næsespray, suspension - 32 mikrogram/dosis
sofradex 0,5 +5,0 +0,05 mg/ml øjen- og øredråber, opløsning
orifarm a/s - dexamethasonnatriumsulfobenzoat, framycetinsulfat, gramicidin - øjen- og øredråber, opløsning - 0,5 +5,0 +0,05 mg/ml
hydrocortison "activase" 10 mg tabletter
activase pharmaceuticals limited - hydrocortison - tabletter - 10 mg
hydrocortison "activase" 20 mg tabletter
activase pharmaceuticals limited - hydrocortison - tabletter - 20 mg
aerivio spiromax
teva b.v. - salmeterol xinafoate, fluticasonpropionat - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - aerivio spiromax er indiceret til brug hos voksne i alderen 18 år og ældre. asthmaaerivio spiromax er indiceret til regelmæssig behandling af patienter med svær astma, hvor anvendelsen af en kombination produkt (inhaleret binyrebarkhormon og langtidsvirkende β2-agonist) er hensigtsmæssige:patienter, der ikke er tilstrækkeligt kontrolleret på et lavere styrke kortikosteroid kombination produkt orpatients allerede kontrolleres på en høj dosis inhaleret binyrebarkhormon og langtidsvirkende β2-agonist. kronisk obstruktiv lungesygdom (kol)aerivio spiromax er indiceret til symptomatisk behandling af patienter med kol med fev1.
airexar spiromax
teva b.v. - salmeterol, fluticasonpropionat - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - airexar spiromax er indiceret til brug kun hos voksne i alderen 18 år og ældre. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. kronisk obstruktiv lungesygdom (kol)airexar spiromax er indiceret til symptomatisk behandling af patienter med kol med fev1.
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).